Literature DB >> 2771165

Quinolinic acid neurotoxicity: protection by intracerebral phenylisopropyladenosine (PIA) and potentiation by hypotension.

J H Connick1, T W Stone.   

Abstract

In the present study we have used the purine agonist R-phenylisopropyladenosine (PIA) which suppresses excitatory amino acid release to assess its effect on quinolinate toxicity. Quinolinic acid was injected into the rat hippocampus alone or with PIA and the animals allowed to recover. After 4 days the brain was removed for histological examination. The extent of neuronal degeneration was assessed blind by an independent observer on a scale of 0 (no damage) to 10 (complete degeneration). Co-administration of PIA protected against the toxicity, and this protective action of PIA was blocked by a xanthine adenosine receptor antagonist. However, systemic injections of PIA or the non-purine ganglion blocking drug trimetaphan, both of which caused significant depression of blood pressure, potentiated quinolinate toxicity. The results may indicate an interaction between endogenous excitotoxins and episodes of hypotension which may be critical in determining cell death in the CNS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2771165     DOI: 10.1016/0304-3940(89)90529-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

2.  The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.

Authors:  David Blum; David Gall; Marie-Christine Galas; Pablo d'Alcantara; Kadiombo Bantubungi; Serge N Schiffmann
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 3.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

4.  Release of endogenous adenosine and its metabolites by the activation of NMDA receptors in the rat hippocampus in vivo.

Authors:  Y Chen; D I Graham; T W Stone
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

5.  Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor.

Authors:  D G MacGregor; W J Miller; T W Stone
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration.

Authors:  D G MacGregor; T W Stone
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

7.  Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.

Authors:  D K Von Lubitz; R C Lin; N Melman; X D Ji; M F Carter; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1994-04-21       Impact factor: 4.432

8.  Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons.

Authors:  Amos A Fatokun; Trevor W Stone; Robert A Smith
Journal:  Exp Brain Res       Date:  2007-11-27       Impact factor: 1.972

9.  NMDA receptor-mediated extracellular adenosine accumulation is blocked by phosphatase 1/2A inhibitors.

Authors:  Yin Lu; Paul A Rosenberg
Journal:  Brain Res       Date:  2007-05-04       Impact factor: 3.252

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.